{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:27:54Z","timestamp":1761870474783,"version":"build-2065373602"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.3816\/clml.2010.s.002","type":"journal-article","created":{"date-parts":[[2010,6,8]],"date-time":"2010-06-08T21:18:41Z","timestamp":1276031921000},"page":"S14-S19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"S1","title":["Applying Cytogenetic and Molecular Information in the Clinic: Implications for the Treatment of Chronic Myeloid Leukemia"],"prefix":"10.3816","volume":"10","author":[{"given":"Alfonso","family":"Quint\u00e1s-Cardama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge E.","family":"Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CLML.2010.s.002_bib1","first-page":"1497","article-title":"A minute chromosome in human chronic granulocytic leukemia","volume":"132","author":"Nowell","year":"1960","journal-title":"Science"},{"key":"10.3816\/CLML.2010.s.002_bib2","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","article-title":"Molecular biology of bcr-abl1-positive chronic myeloid leukemia","volume":"113","author":"Quintas-Cardama","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.002_bib3","first-page":"3231","article-title":"The first intron in the human c-abl gene is at least 200 kilobases long and is a target for translocations in chronic myelogenous leukemia","volume":"7","author":"Bernards","year":"1987","journal-title":"Mol Cell Biol"},{"key":"10.3816\/CLML.2010.s.002_bib4","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1200\/JCO.1988.6.10.1569","article-title":"Philadelphia-negative chronic myelogenous leukemia with breakpoint cluster region rearrangement: molecular analysis, clinical characteristics, and response to therapy","volume":"6","author":"Shtalrid","year":"1988","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.s.002_bib5","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.2408149","article-title":"Tyrosine kinase activity and transformation potency of bcr-abl oncogene products","volume":"247","author":"Lugo","year":"1990","journal-title":"Science"},{"key":"10.3816\/CLML.2010.s.002_bib6","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0165-4608(02)00558-7","article-title":"Correlation of three methods of measuring cytogenetic response in chronic myelocytic leukemia","volume":"137","author":"Lesser","year":"2002","journal-title":"Cancer Genet Cytogenet"},{"key":"10.3816\/CLML.2010.s.002_bib7","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/sj.leu.2403077","article-title":"FISH for BCR-ABL on interphases of peripheral blood neutrophils but not of unselected white cells correlates with bone marrow cytogenetics in CML patients treated with imatinib","volume":"17","author":"Reinhold","year":"2003","journal-title":"Leukemia"},{"key":"10.3816\/CLML.2010.s.002_bib8","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1053\/shem.2003.50044","article-title":"Molecular monitoring of chronic myeloid leukemia","volume":"40","author":"Hughes","year":"2003","journal-title":"Semin Hematol"},{"key":"10.3816\/CLML.2010.s.002_bib9","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"key":"10.3816\/CLML.2010.s.002_bib10","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.002_bib11","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.3816\/CLML.2010.s.002_bib12","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1182\/blood.V114.22.1126.1126","article-title":"International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib","volume":"114","author":"Deininger","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.002_bib13","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1182\/blood-2006-02-004325","article-title":"Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia","volume":"108","author":"Kantarjian","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.002_bib14","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1182\/blood-2006-02-001495","article-title":"Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials","volume":"108","author":"Roy","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.002_bib15","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1002\/cncr.24325","article-title":"Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia","volume":"115","author":"Quintas-Cardama","year":"2009","journal-title":"Cancer"},{"key":"10.3816\/CLML.2010.s.002_bib16","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.s.002_bib17","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1002\/cncr.24418","article-title":"Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase","volume":"115","author":"Alvarado","year":"2009","journal-title":"Cancer"},{"key":"10.3816\/CLML.2010.s.002_bib18","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.3816\/CLML.2010.s.002_bib19","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1182\/blood.V112.11.76.76","volume":"112","author":"O\u2019Brien","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.002_bib20","doi-asserted-by":"crossref","first-page":"7519","DOI":"10.1158\/1078-0432.CCR-09-1068","article-title":"Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia","volume":"15","author":"Milojkovic","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLML.2010.s.002_bib21","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.002_bib22","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","article-title":"Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia","volume":"26","author":"Shah","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.s.002_bib23","doi-asserted-by":"crossref","first-page":"16a","DOI":"10.1182\/blood.V110.11.27.27","article-title":"Time to complete cytogenetic response (CCyR) does not affect long-term outcomes for patients on imatinib therapy","volume":"110","author":"Guilhot","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.002_bib24","doi-asserted-by":"crossref","first-page":"6315","DOI":"10.1182\/blood-2008-07-166694","article-title":"Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy","volume":"113","author":"Quintas-Cardama","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.002_bib25","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1038\/leu.2009.156","article-title":"Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"10.3816\/CLML.2010.s.002_bib26","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1182\/blood-2008-06-161737","article-title":"Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg\/day of imatinib as initial therapy","volume":"112","author":"Hughes","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.002_bib27","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1182\/blood-2008-02-141580","article-title":"Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.002_bib28","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1158\/1078-0432.CCR-04-2139","article-title":"Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate","volume":"11","author":"Cortes","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLML.2010.s.002_bib29","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1200\/JCO.2008.18.6999","article-title":"Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response","volume":"27","author":"Kantarjian","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.s.002_bib30","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.1158\/1078-0432.CCR-07-1112","article-title":"A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response","volume":"13","author":"Press","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLML.2010.s.002_bib31","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1182\/blood-2008-08-173674","article-title":"Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib","volume":"114","author":"Press","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.002_bib32","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1365-2141.2009.07646.x","article-title":"Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?","volume":"145","author":"Marin","year":"2009","journal-title":"Br J Haematol"},{"key":"10.3816\/CLML.2010.s.002_bib33","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1182\/blood-2004-03-1134","article-title":"Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations","volume":"104","author":"Branford","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.002_bib34","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance and the road to a cure of chronic myeloid leukemia","volume":"110","author":"O\u2019Hare","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.002_bib35","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1200\/JCO.2008.19.8853","article-title":"Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR\/ABL mutants","volume":"27","author":"Redaelli","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.s.002_bib36","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1200\/JCO.2009.21.8230","article-title":"Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase","volume":"27","author":"Hughes","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.s.002_bib37","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2009-04-214221","article-title":"Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations","volume":"114","author":"Muller","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.002_bib38","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1182\/blood-2009-01-197715","article-title":"Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations","volume":"114","author":"Jabbour","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.002_bib39","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3324\/haematol.2009.012781","article-title":"Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia","volume":"95","author":"Milojkovic","year":"2009","journal-title":"Haematologica"},{"key":"10.3816\/CLML.2010.s.002_bib40","first-page":"210","article-title":"Predictive factors for response and outcome in patients (pts) treated with second generation tyrosine kinase inhibitors (2-TKI) for chronic myeloid leukemia in chronic phase (CML-CP) post imatinib failure","volume":"114","author":"Jabbour","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.002_bib41","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood.V114.22.505.505","article-title":"Sustained complete molecular response to imatinib in chronic myeloid leukemia (CML): a target worth aiming and achieving?","volume":"114","author":"Verma","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.s.002_bib42","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1182\/blood.V114.22.859.859","article-title":"Discontinuation of imatinib therapy after achieving a molecular response in chronic myeloid leukemia patients","volume":"114","author":"Mahon","year":"2009","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011700544?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011700544?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:22:53Z","timestamp":1761870173000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265011700544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":42,"alternative-id":["S2152265011700544"],"URL":"https:\/\/doi.org\/10.3816\/clml.2010.s.002","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2010,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Applying Cytogenetic and Molecular Information in the Clinic: Implications for the Treatment of Chronic Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CLML.2010.s.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}